HCP Live September 27, 2024
To date, biosimilars have supported 495 million incremental days of therapy that patients would otherwise not have received.
Savings from the use of biosimilar medicines reached $12.4 billion in 2023, according to the Association for Accessible Medicines’ and Biosimilars Council’s 2024 U.S. Generic & Biosimilar Medicines Savings Report.1
“The good news: biosimilars continue to deliver quality care at lower prices,” Craig Burton, Executive Director for the Biosimilars Council, said in a statement.1 “However, the biosimilars market faces severe challenges to its long-term sustainability. Swift legislative and regulatory action to safeguard biosimilar competition is vital.”
Overall, biosimilars have generated $36 billion in savings since their introduction to the market in 2015 and have repeatedly demonstrated their safety and effectiveness with no...
Today's Sponsors
Today's Sponsor